First Analysis initiated coverage on shares of NeoGenomics Inc. (NASDAQ:NEO) in a report released on Monday, The Fly reports. The brokerage set an “overweight” rating on the stock.
NEO has been the subject of several other research reports. Raymond James Financial Inc. started coverage on NeoGenomics in a research note on Thursday, September 8th. They issued an “outperform” rating and a $10.00 price target for the company. Zacks Investment Research raised NeoGenomics from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a research report on Friday, August 5th. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of NeoGenomics in a research report on Friday, July 8th. Benchmark Co. upped their target price on NeoGenomics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, July 27th. Finally, Craig Hallum reaffirmed a “buy” rating on shares of NeoGenomics in a research report on Saturday, July 9th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $10.32.
Shares of NeoGenomics (NASDAQ:NEO) traded down 1.764% during mid-day trading on Monday, hitting $8.075. 130,592 shares of the company were exchanged. NeoGenomics has a 12-month low of $5.49 and a 12-month high of $9.54. The stock’s 50-day moving average price is $8.11 and its 200 day moving average price is $8.09. The stock’s market cap is $628.99 million.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, July 26th. The company reported $0.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.01. The business earned $63.10 million during the quarter, compared to analysts’ expectations of $61.07 million. NeoGenomics had a positive return on equity of 3.18% and a negative net margin of 3.76%. The firm’s quarterly revenue was up 159.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.01 EPS. On average, equities analysts anticipate that NeoGenomics will post $0.13 EPS for the current fiscal year.
In other news, insider Maher Albitar sold 370,000 shares of the company’s stock in a transaction that occurred on Friday, August 19th. The stock was sold at an average price of $8.23, for a total transaction of $3,045,100.00. Following the completion of the transaction, the insider now directly owns 263,492 shares in the company, valued at $2,168,539.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 12.20% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Suntrust Banks Inc. acquired a new position in shares of NeoGenomics during the second quarter worth approximately $114,000. Cambridge Investment Research Advisors Inc. raised its position in shares of NeoGenomics by 29.1% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 15,300 shares of the company’s stock worth $123,000 after buying an additional 3,450 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of NeoGenomics by 1.1% in the second quarter. State Board of Administration of Florida Retirement System now owns 17,810 shares of the company’s stock worth $143,000 after buying an additional 190 shares during the last quarter. KCG Holdings Inc. purchased a new position in shares of NeoGenomics during the second quarter worth approximately $146,000. Finally, Trexquant Investment LP purchased a new position in shares of NeoGenomics during the second quarter worth approximately $166,000. Institutional investors own 77.20% of the company’s stock.
NeoGenomics Company Profile
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.